• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Kintara Therapeutics Inc.

    10/4/24 4:10:02 PM ET
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTRA alert in real time by email
    425 1 ktra_425_20241004_sh_mee.htm 425 425

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 4, 2024

     

     

    KINTARA THERAPEUTICS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Nevada

    001-37823

    99-0360497

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9920 Pacific Heights Blvd

    Suite 150

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 350-4364

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock

     

    KTRA

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    As previously disclosed, on September 20, 2024, Kintara Therapeutics, Inc. (“Kintara”) convened and adjourned its 2024 Special Meeting of Stockholders (the “Special Meeting”) to October 4, 2024. On October 4, 2024, Kintara reconvened the Special Meeting being held to consider and vote on the following proposals: (a) the proposal to approve the issuance of shares of common stock of Kintara (the “Common Stock”) (such shares, the “Merger Shares”) issuable in connection with the Agreement and Plan of Merger, dated as of April 2, 2024 (the “Merger Agreement”), by and among Kintara, TuHURA Biosciences, Inc. (“TuHURA”) and Kayak Mergeco, Inc. (“Merger Sub”) (the “Nasdaq Proposal”); (b) the proposal to approve, pursuant to Nevada Revised Statutes 78.2055, a reverse stock split of only the outstanding shares of Kintara’s Common Stock and other outstanding securities of Kintara (with no change to the authorized capital stock of Kintara) at a ratio ranging from 1-for-20 to 1-for-40, with such ratio to be determined in the discretion of Kintara’s board of directors and with such reverse stock split to be effected at such time and date as determined by Kintara’s board of directors in its sole discretion (the “Reverse Stock Split Proposal”); (c) the proposal to approve an increase in the number of authorized shares of Kintara’s Common Stock to 400,000,000, to be effected at such time and date as determined by Kintara’s board of directors in its sole discretion (the “Charter Proposal”); (d) the proposal to approve the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan, which was approved by Kintara’s board of directors on August 7, 2024 subject to stockholder approval at the Special Meeting and upon consummation of the merger of Merger Sub with and into TuHURA (the “Merger”), with TuHURA surviving the Merger as a wholly-owned subsidiary of Kintara (the “2024 Equity Plan Proposal”); (e) the proposal to approve a change the state of incorporation of Kintara from the State of Nevada to the State of Delaware (the “Reincorporation”) and the plan of conversion attached to the proxy statement/prospectus as Annex D including the certificate of incorporation of Kintara following consummation of the Reincorporation attached to the proxy statement/prospectus as Annex G (the “Reincorporation Proposal”); (f) the proposal to approve, in a non-binding advisory vote, certain compensation payments that will or may be made to one of Kintara’s named executive officers, Robert E. Hoffman, in connection with the Merger (the “Golden Parachute Proposal”); and (g) the proposal to adjourn the Special Meeting for the purpose of soliciting additional proxies if any of proposals (a)-(f) above (collectively, the “Kintara Proposals”) do not receive a sufficient number of votes for approval (the “Adjournment Proposal”).

     

    Present at the reconvened Special Meeting, in person or by proxy, were holders of 32,634,850 shares of Kintara’s Common Stock and Series C Preferred Stock (on an as-converted basis), representing at least one-third of the voting power of the capital stock issued and outstanding and entitled to vote at the Special Meeting as of August 14, 2024 (the “Record Date”), which constituted a quorum for the transaction of business.

    The voting results for each item of business voted upon at the Special Meeting were as follows:

    The Nasdaq Proposal – Approval of the issuance of the Merger Shares and the change of control of Kintara following the Merger:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    26,751,464

    1,175,318

    204,170

    4,503,898

    As a result, the Nasdaq Proposal was approved by the requisite vote of Kintara’s stockholders.

     

    The Reverse Stock Split Proposal – Approval of a reverse stock split at a ratio in the range from 1-for-20 to 1-for-40:

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    27,090,705

    5,184,882

    278,845

    80,418

    As a result, the Reverse Stock Split Proposal was approved by the requisite vote of Kintara’s stockholders.

     

    The Charter Proposal – Approval of an increase in the number of authorized shares of Kintara’s Common Stock to 400,000,000:

     

     

     


     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    26,632,610

    5,708,824

    293,416

    0

     

    As a result, the Charter Proposal was not approved by the requisite vote of Kintara’s stockholders.

     

    The 2024 Equity Plan Proposal – Approval of the TuHURA 2024 Equity Incentive Plan:

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    22,479,659

    5,099,707

    632,004

    4,423,480

    As a result, the 2024 Equity Plan Proposal was approved by the requisite vote of Kintara’s stockholders.

     

    The Reincorporation Proposal – Approval of a change the state of incorporation of Kintara from the State of Nevada to the State of Delaware:

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    26,530,701

    1,290,576

    309,861

    4,503,712

     

    As a result, the Reincorporation Proposal was not approved by the requisite vote of Kintara’s stockholders.

     

    The Golden Parachute Proposal – Approval of, in a non-binding advisory vote, certain compensation payments that will or may be made to Kintara’s named executive officer:

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    17,021,190

    9,659,427

    1,530,753

    4,423,480

     

    As a result, the Golden Parachute Proposal was approved by the requisite vote of Kintara’s stockholders on an advisory basis.

     

    The Adjournment Proposal – Adjourning the Special Meeting to solicit additional proxies to approve the Kintara Proposals:

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    25,700,409

    6,310,817

    623,623

    1

     

    As a result, the Adjournment Proposal was approved by the requisite vote of Kintara’s stockholders. The Adjournment Proposal was deemed not necessary and not acted upon at the Special Meeting as a result of the approval of the Nasdaq Proposal, the Reverse Stock Split Proposal, the 2024 Equity Plan Proposal and the Golden Parachute Proposal.

     

    Following receipt of stockholder approval of the Nasdaq Proposal, the Reverse Stock Split Proposal, the 2024 Equity Plan Proposal and the Golden Parachute Proposal, Kintara and TuHURA expect to consummate the Merger in mid-October 2024, subject to the satisfaction of the remaining closing conditions under the Merger Agreement.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements based upon Kintara’s and TuHURA’s current expectations. This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara’s and TuHURA’s control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the

     


     

    conditions to the closing or consummation of the proposed Merger are not satisfied; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara’s and TuHURA’s ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; (iv) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the proposed Merger by either Kintara or TuHURA; (v) the effect of the announcement or pendency of the proposed Merger on Kintara’s or TuHURA’s business relationships, operating results and business generally; (vi) costs related to the proposed Merger; (vii) the outcome of any legal proceedings that may be instituted against Kintara, TuHURA, or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby; (vii) the ability of Kintara or TuHURA to protect their respective intellectual property rights; (viii) competitive responses to the proposed Merger; (ix) unexpected costs, charges or expenses resulting from the proposed Merger; (x) whether the combined business of TuHURA and Kintara will be successful; (xi) legislative, regulatory, political and economic developments; and (xii) additional risks described in the “Risk Factors” section of Kintara’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, and the registration statement on Form S-4 related to the proposed Merger filed with the SEC. Additional assumptions, risks and uncertainties are described in detail in Kintara’s registration statements, reports and other filings with the SEC, which are available on Kintara’s website, and at www.sec.gov. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Neither Kintara nor TuHURA can assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, Kintara and TuHURA undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Investors should not assume that any lack of update to a previously issued “forward-looking statement” constitutes a reaffirmation of that statement.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    KINTARA THERAPEUTICS, INC.

    Date: October 4, 2024

    By:

    /s/ Robert E. Hoffman

    Name: Robert E. Hoffman

    Title: Chief Executive Officer

     


    Get the next $KTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KTRA

    DatePrice TargetRatingAnalyst
    1/20/2022$6.00 → $3.00Buy
    HC Wainwright & Co.
    9/30/2021$7.00 → $5.00Buy
    Aegis Capital
    9/28/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KTRA
    SEC Filings

    See more
    • Kintara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/21/24 8:30:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Kintara Therapeutics Inc.

      EFFECT - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/16/24 12:15:03 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/15/24 4:20:08 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 9:12:33 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:50:14 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ng George K

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:47:13 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

      SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger

      10/16/24 12:54:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

      SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.

      10/16/24 11:58:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

      SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint

      10/15/24 4:15:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

      SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)

      2/13/23 4:29:24 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kintara Therapeutics Inc.

      SC 13G - Kintara Therapeutics, Inc. (0001498382) (Subject)

      4/20/22 5:11:42 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

      SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)

      2/7/22 1:26:53 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $3.00 from $6.00 previously

      1/20/22 5:37:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on Kintara Therapeutics with a new price target

      Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      9/30/21 9:44:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $6.00

      9/28/21 6:18:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Financials

    Live finance-specific insights

    See more
    • Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

      SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, w

      10/8/24 7:00:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

      SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments. Recent Corporate Developments Announced that Kintara had entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Merge

      5/14/24 4:45:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

      TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunitiesCompanies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ETSAN DIEGO and TAMPA, Fla., April 3, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a bi

      4/3/24 7:00:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

      SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

      5/4/21 8:00:00 AM ET
      $KTRA
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining, Mirasol Resources and OTC Markets Group

      New York, March 03, 2021 (GLOBE NEWSWIRE) -- - Medexus Pharmaceuticals Inc (CVE:MDP)  shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results click here - BioPorto A/S  (CPH:BIOPOR) expects to complete its clinical study and submit a De Novo application to the US FDA for pediatric use of its NGAL kidney test this summer click here  - EVmo  Inc (OTCMKTS:YAYO) closes its controlling interest sale to Acuitas Group Holdings click here - Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) brings on Camargo Pharmaceutical Services to boost US FDA approval for Ivectsol click here - Alpine 4 Technologies Ltd (OTCQB:ALPP) appoi

      3/3/21 2:25:29 PM ET
      $KTRA
      $PHUN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      EDP Services
      Technology
    • Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer

      SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). "We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication," commented Saiid Zarrabian, Kintara's Chief Executive Officer. "We look forward to working closely with Dr. La

      3/3/21 8:00:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care